Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants increase the risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. We performed a pooled analysis to evaluate the relationship between NNRTI-resistant minority variants and the likelihood and types of resistance mutations detected at virologic failure. In multivariable logistic regression analysis, higher NNRTI minority variant copy numbers, non-white race, and nevirapine use were associated with a higher risk of NNRTI resistance at virologic failure. Among participants on efavirenz, K103N was the most frequently observed resistance mutation at virologic failure regardless of the baseline minority variant. However, the presence of baseline Y181C minority variant was associated with a higher probability of Y181C detection after virologic failure. NNRTI regimen choice and preexisting NNRTI-resistant minority variants were both associated with the probability and type of resistance mutations detected after virologic failure.

[1]  K. Mcintosh,et al.  Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment: A Bayesian Analysis , 2011, PloS one.

[2]  K. Borroto-Esoda,et al.  Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy , 2011, AIDS.

[3]  Feng Gao,et al.  Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment , 2010, Antimicrobial Agents and Chemotherapy.

[4]  R. Paredes,et al.  Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. , 2010, Antiviral research.

[5]  S. Hammer,et al.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.

[6]  R. Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[7]  P. Gorry,et al.  Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  W. Heneine,et al.  Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy , 2009, Journal of acquired immune deficiency syndromes.

[9]  B. Agan,et al.  Virologic Response Differences Between African Americans and European Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to Care , 2009, Journal of acquired immune deficiency syndromes.

[10]  James Theiler,et al.  Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo , 2009, PloS one.

[11]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[12]  K. Metzner,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[14]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[15]  J. Eshleman,et al.  Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. , 2006, The Journal of molecular diagnostics : JMD.

[16]  K. Tashima,et al.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. Richman,et al.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. , 2000, The Journal of infectious diseases.

[18]  B. Larder,et al.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.

[19]  髙折 晃史,et al.  19th Conference on Retroviruses and Opportunistic Infections , 2012 .

[20]  K. Metzner,et al.  Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure , 2011 .

[21]  E. Yuste,et al.  In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. , 2002, The Journal of general virology.